Replies to post #198522 on Biotech Values

[oc631]

Anyone have any comments on likelihood this will differentiate MK-8931 from the litany of prior AD drugs targeting amyloid beta that have failed in the clinic?

So far no news has been good news concerning safety. In terms of differentiation, the angle you may be looking for could be in the study design using prodromal patients. Still a long shot. I look at MK-8931 as an underlying call option on the best long-term, risk adjusted play in biotech.

The CVR's under Cydex agreement (Captisol) expire near the end of next year so sales and licensing proceeds will go directly to LGND's bottom line. Sure a strong argument could be made the stock is currently overvalued. People have been saying that for years.

[biomaven0]

- LGND

Have to believe the AD drug is a long shot.

For me the hidden LGND gem might be their glucagon antagonist - it's perhaps significant that this is one drug they didn't spin off but are developing themselves.

I've owned the stock for many years now - just figured it made a nice change from all the other high risk stuff I own.

Peter